In a large Phase III trial, GlaxoSmithKline's Arexvy substantially reduced people's risk of severe complications from respiratory syncytial virus infection.
In people over 60, the mRNA-based vaccine appeared over 80% effective at preventing symptoms linked to lower respiratory infections caused by the virus.
OLYMPIA – With the cooler weather comes traditional holiday gatherings with friends and family. Amid a strained hospital system, an early and more severe respiratory virus season, and people gathering to celebrate, the Washington State Department of Health (DOH) would like to remind everyone how to stay safe and healthy this holiday season.